Back to Search Start Over

PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT‐ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL‐WORLD SINGLE CENTER EXPERIENCE.

PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT‐ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL‐WORLD SINGLE CENTER EXPERIENCE.

Authors :
Elsabah, H.
Kassem, N.
Gulied, A.
Taha, R.
Elomri, H.
Cherif, H.
Source :
HemaSphere; 2022 Supplement 3, Vol. 6, p1868-1869, 2p
Publication Year :
2022

Details

Language :
English
ISSN :
25729241
Volume :
6
Database :
Complementary Index
Journal :
HemaSphere
Publication Type :
Academic Journal
Accession number :
175309039
Full Text :
https://doi.org/10.1097/01.HS9.0000850820.70181.23
Full Text Access
View/download PDF

Tools

Authors Abstract Subjects Details